首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 非專利藥 > 加拿大的學名藥市場：市場預測（∼2012年）
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

加拿大的學名藥市場：市場預測（∼2012年）

Generic Drug Market in Canada

出版商 RNCOS E-Services Pvt. Ltd.
出版日期 2010年11月 商品編碼 136280
內容資訊 英文 70 Pages
價格
本報告書已不再販售

本報告已在2011年12月14日停止出版。

更改為出版

加拿大的學名藥市場
Generic Drug Market in Canada
出版日期 : 2011年11月
商品編碼: 223495

簡介

本報告，調查分析加拿大學名藥市場的現狀與展望，並彙整加拿大市場的社會・經濟背景、醫療基礎建設、主要市場動向、學名藥的處方件數與業績的變化、與原廠藥的比較、區域・疾病・銷售管道別的動向、相關法規環境、主要企業的檔案資料等，由下列摘要形式闡述。

第1章 分析師的見解

第2章 宏觀經濟・醫療相關因子

  • 宏觀經濟指標
  • 人口資料
  • 年齡資料
  • 醫療費用支出・基礎建設

第3章 市場動向

  • 高血壓用學名藥
  • 低價化學名藥
  • 專利期滿

第4章 學名藥市場的表現

  • 市場規模・市場成長率
    • 學名藥與原廠藥的處方件數
    • 學名藥與原廠藥的業績額
  • 區域別
    • 醫藥品使用
    • 處方件數
    • 業績額
  • 銷售管道別
    • 零售藥局
    • 醫院內的藥局
    • 認可的學名藥・獨立型學名藥
    • 銷售管道
  • 疾病別
    • 心血管治療藥物
    • 精神病治療藥物
    • 高血脂症治療藥物
    • 抗糖尿病藥物

第5章 法規環境

第6章 競爭環境

  • 市場結構
  • 主要企業分析
    • Apotex
    • Teva Canada Ltd. (Novopharm)
    • Mylan
    • Pharmascience

圖表

目錄

Abstract

Canada has established itself as one of the largest pharmaceuticals markets globally and provides tremendous opportunity for generics. In 2009, generics accounted for more than 54% prescriptions and around 24% sales of the total pharmaceutical market. Patent expiration of branded drugs, rapidly ageing population, and the government support through cost reduction measures are some of the factors that are boosting the industry growth. The market for generic drugs is expected to reach CAD 9.4 Billion in 2013 from CAD 5.5 Billion in 2009, growing at a CAGR of more than 14% during the period.

According to our latest market research report entitled “Generic Drug Market in Canada”, steps taken by the provincial governments in ensuring availability of drugs at affordable cost and billion dollar drug patent expiries will prove to be a major growth booster for the industry. Besides, the government is adopting measures that will enhance the supply proportion of generic drugs and rebates offered (to pharmacies) will augment revenue patterns.

Our report has identified that, currently, cardiovascular drugs retain the top position in terms of total prescription and the amount of prescriptions has grown by 4% in 2009 over 2008. However, oncology remained at the top position in terms of hospital sales with CAD 808.1 Million revenue in 2009. Other therapy areas such as diabetes and hypertension are expected to drive the generics market in Canada in future.

The report covers all the necessary ingredients of Canadian generics sector and distinguishes domestic market form other generics market in terms of both positive and negative ways. A notable factor of comparison that differentiates the Canadian generics market from the US and most European markets, for instance, is comparatively higher prices of generics and lower price erosion. However, the latest regulatory mechanism clearly shows that the Canadian government has been adopting measures to ensure optimum generic costs.

“Generic Drug Market in Canada” provides extensive research and objective analysis of the generic drug market in Canada. The report effectively evaluates all the factors that are driving the growth and studies current market trends that will shape the future of the industry. The report also examines the performance of various players in the Canadian pharmaceutical and generic markets. Besides, a number of factors, which can deteriorate the future market growth, have been discussed in the report.

Table of Contents

1. Analyst View

2. Macroeconomic and Healthcare Factors

  • 2.1 Macroeconomic Indicators
  • 2.2 Population Profile
  • 2.3 Age Profile
  • 2.4 Healthcare Spending and Infrastructure

3. Market Trends

  • 3.1 Generic Drugs for Hypertension
  • 3.2 Generics Getting Affordable
  • 3.3 Patent Expiration

4. Generics Market Performance

  • 4.1 Market Size and Growth
    • 4.1.1 Prescriptions
    • 4.1.2 Sales
  • 4.2 By Province/Territories
    • 4.2.1 Drug Consumption
    • 4.2.2 Prescriptions
    • 4.2.3 Sales
  • 4.3 By Distribution
    • 4.3.1 Retail Pharmacies
    • 4.3.2 Hospital Pharmacies
    • 4.3.3 Authorized and Independent Generics
    • 4.3.4 Distribution Channels
  • 4.4 By Disease
    • 4.4.1 Cardiovascular Drugs
    • 4.4.2 Psychotherapeutics
    • 4.4.3 Cholesterol Agents
    • 4.4.4 Antidiabetics

5. Regulatory Environment

6. Competitive Landscape

  • 6.1 Market Structure
  • 6.2 Key Players Analysis
    • 6.2.1 Apotex
    • 6.2.2 Teva Canada Ltd. (Novopharm)
    • 6.2.3 Mylan
    • 6.2.4 Pharmascience

List of Figures:

  • Figure 2-1: Nominal GDP (Billion US$), 2007-2009
  • Figure 2-2: Consumer Price Index (%), 2009-2013
  • Figure 2-3: Population (Million), 2009-2013
  • Figure 2-4: Life Expectancy (Years), 2009-2013
  • Figure 2-5: Population Breakup by Age Group (%), 2009-2013
  • Figure 2-6: Per Head Healthcare Spending (US$), 2009-2013
  • Figure 2-7: Number of Doctors (2009-2013)
  • Figure 2-8: Number of Hospital Beds (per ‘000 Population), 2009-2013
  • Figure 4-1: Pharmaceutical Sales (Billion CAD), 2009-2013
  • Figure 4-2: Prescriptions Dispensed in Branded Drug Market (Million), 2005-2009
  • Figure 4-3: Prescriptions Dispensed in Generic Drug Market (Million), 2005-2009
  • Figure 4-4: Share of Generic and Branded Drug by Prescription (2005-2009)
  • Figure 4-5: Average Retail Price of Branded and Generic Drug (CAD), 2005-2009
  • Figure 4-6: Generic Drug Sales (Billion CAD), 2009-2013
  • Figure 4-7: Branded Drug Sales (Billion CAD), 2009-2013
  • Figure 4-8: Share of Generic and Branded Drug by Sales (2009-2013)
  • Figure 4-9: Branded Drug Sales through Retail Pharmacies (Billion CAD), 2009-2013
  • Figure 4-10: Generic Drug Sales through Retail Pharmacies (Billion CAD), 2009-2013
  • Figure 4-11: Share of Generic and Branded Drug Sales through Retail Pharmacies (2009-2013)
  • Figure 4-12: Branded Drug Sales through Hospital Pharmacies (Billion CAD), 2009-2013
  • Figure 4-13: Generic Drug Sales through Hospital Pharmacies (Billion CAD), 2009-2013
  • Figure 4-14: Share of Generic and Branded Drug Sales through Hospital Pharmacies (2009-2013)
  • Figure 4-15: Share of Independent Generic and Authorized Generic Prescriptions (2005-2008)
  • Figure 4-16: Generic Drug Market by Retail and Hospital Sales (%), 2009
  • Figure 4-17: Cardiovascular Drug Market (Billion CAD), 2005-2009 & 2013
  • Figure 4-18: Psychotherapeutics Market (Billion CAD), 2005-2009 & 2013
  • Figure 4-19: Cholesterol Agents Market (Billion CAD), 2005-2009 & 2013
  • Figure 4-20: Number of Diabetes Patients in Age Group 20-79 Years (Million), 2010 & 2030
  • Figure 4-21: Diabetes Therapy Market (Million CAD), 2005-2009 & 2013

List of Tables:

  • Table 3-1: Patent Expiration for Some Hypertension Drugs (2012)
  • Table 3-2: Patent Expiration of Key Drugs (2011)
  • Table 4-1: Top Ten Therapy Areas by Prescription (‘000), 2009
  • Table 4-2: Per Capita Drug Spending of Public and Private Sector by Region (CAD), 2009
  • Table 4-3: Generic Drug Prescriptions Dispensed by Region (%), 2005-2009
  • Table 4-4: Generic Drug Sales by Region (%), 2004 & 2006
  • Table 4-5: Number of Retail Pharmacies by Category (2005-2010)
  • Table 4-6: Top Ten Therapy Areas by Hospital Sales (Million CAD), 2009
  • Table 6-1: Top Pharmaceutical Companies by Sales (Million CAD), 2009
  • Table 6-2: Top Generic Drug Companies by Prescription (Million), 2007
  • Table 6-3: Top Generic Drug Companies by Sales (Million CAD), 2007
  • Table 6-4: Apotex - Strengths & Weaknesses
  • Table 6-5: Teva Canada Ltd. (Novopharm) - Strengths & Weaknesses
  • Table 6-6: Mylan - Strengths & Weaknesses
Back to Top